Marka R. Crittenden
Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice
Crittenden, Marka R.; Savage, Talicia; Cottam, Benjamin; Baird, Jason; Rodriguez, Paulo C.; Newell, Pippa; Young, Kristina; Jackson, Andrew M.; Gough, Michael J.
Paulo C. Rodriguez
ANDREW JACKSON email@example.com
Michael J. Gough
An accumulating body of evidence demonstrates that radiation therapy can generate adaptive immune responses that contribute to tumor control. However, in the absence of additional immune therapy, the adaptive immune response is insufficient to prevent tumor recurrence or affect distant disease. It has been shown in multiple models that tumor-infiltrating myeloid cells exhibit alternative activation phenotypes and are able to suppress adaptive immune responses, and recent data suggests that the myeloid response in tumors treated with cytotoxic therapy limits tumor control. We hypothesized that tumor myeloid cells inhibit the adaptive immune response after radiation therapy through expression of the enzyme arginase I. Using a myeloid cell-specific deletion of arginase I in mice, we demonstrate an improved tumor control after radiation therapy. However, tumors still recurred despite the conditional knockdown of arginase I. Since multiple alternative factors may combine to inhibit adaptive immunity, we propose that targeting macrophage differentiation may be a more effective strategy than targeting individual suppressive pathways.
|Journal Article Type||Article|
|Publisher||Radiation Research Society|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Crittenden, M. R., Savage, T., Cottam, B., Baird, J., Rodriguez, P. C., Newell, P., …Gough, M. J. (2014). Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice. Radiation Research, 182(2), 182-190. https://doi.org/10.1667/rr13493.1|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf|
You might also like
Breast cancer stem cells: A fallow research ground in Africa
Connexin 43 is an independent predictor of patient outcome in breast cancer patients
Identification of particle-laden flow features from wavelet decomposition